Dyne Therapeutics (NASDAQ:DYN) Director Sells 95,900 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 95,900 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $21.02, for a total value of $2,015,818.00. Following the completion of the sale, the director directly owned 1,086,063 shares in the company, valued at $22,829,044.26. This trade represents a 8.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $20.61 on Friday. The business has a fifty day moving average price of $18.43 and a 200-day moving average price of $18.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The company has a market capitalization of $3.41 billion, a PE ratio of -6.40 and a beta of 1.09. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the firm posted ($1.05) earnings per share. As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Hilton Head Capital Partners LLC bought a new stake in Dyne Therapeutics during the first quarter valued at approximately $26,000. Strs Ohio purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth $51,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth $84,000. Steward Partners Investment Advisory LLC lifted its stake in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Dyne Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after buying an additional 1,440 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DYN. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a report on Friday, May 15th. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. HC Wainwright cut their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Finally, Morgan Stanley decreased their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $34.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.